Prevalence of Adrenal Insufficiency in Kidney Transplanted Patients in

Status Completed

Clinical Trial Summary

The primary purpose of this study is to determine the prevalence of adrenal insufficiency in a population of patients with kidney transplants receiving low dose prednisone treatment. Development of glucocorticoid-induced adrenal insufficiency is a serious adverse effect to glucocorticoid treatment. The study includes a control group of patients with kidney failure currently treated in dialysis, who are not in glucocorticoid treatment. Individual genotyping is performed to determine the haplotype of glucocorticoid receptor polymorphisms: N363 S, BclI, ER23/23EK and 9β in all the patients with the purpose of investigating this as a risk factor for the development of adrenal insufficiency. The hypothesis is that subjects with one or another of the polymorphisms in the glucocorticoid receptor gene will either have increased or diminished glucocorticoid sensitivity. Using validated questionnaires assessing the quality of life and functional level of the patients enrolled in the study we aim to establish a link between functional level and biochemically proven adrenal insufficiency. Other secondary outcomes in the study includes bloodpressure, body composition, bone density, metabolic syndrome, inflammation and salivary cortisol profiles.

Clinical Trial Description

Adrenal function is assessed in 30 prednisolon treated kidney transplanted patients and compared with 30 patients in dialysis, who are not treated with glucocorticoids. Adrenal function is evaluated using a 250µg Synacthen® test, performed fasting, in the morning, 48 h after the last prednisolone dose. Cut-off for normal adrenal function is locally validated assay specific cut-off of 30 min P-cortisol >420 nmol/l. The primary outcome measure of this study is P-cortisol concentrations 30 minutes after Synacthen® injection in prednisolone treated patients compared with comtrols. Secondary, 30 minutes P-cortisol is examined in relation to glucocorticoid receptor haplotypes. The genotyping is determined using polymerase chain reaction (PCR). The questionnaires used in this study includes EQ-5D, SF-36, Patient Life Situation Form, CushingQol and ADDOQol. ;

Study Design

Related Conditions & MeSH terms

Adrenal Insufficiency

Clinical Trial Details

NCT number	NCT03136562
Study type	Observational
Source	Rigshospitalet, Denmark
Contact
Status	Completed
Phase
Start date	March 20, 2017
Completion date	June 1, 2019

View Details

See also
Status	Clinical Trial	Phase
Enrolling by invitation	`NCT03282487` - Optimising Steroid Replacement in Patients With Adrenal Insufficiency	Phase 4
Not yet recruiting	`NCT05716607` - Treatment Study in Patients Treated With Both Insulin & Hydrocortisone	N/A
Not yet recruiting	`NCT06435481` - Tolerability and Acceptance of Two Oral Hydrocortisone Compounding Formulation for Pediatrics	Phase 4
Recruiting	`NCT03399383` - Adherence in Chronic Adrenal Insufficiency	N/A
Completed	`NCT01428336` - Value of 25 mcg Cortrosyn Stimulation Test	N/A
Completed	`NCT00851942` - Determination of Method-specific Normal Cortisol and Adrenal Hormone Responses to the Short Synacthen Test	Phase 4
Withdrawn	`NCT00368381` - Hydrocortisone Versus Hydrocortisone Plus Fludrocortisone for the Treatment of Adrenal Insufficiency in Severe Sepsis	Phase 4
Active, not recruiting	`NCT04519580` - Improved Diagnostics and Monitoring of Polymyalgia Rheumatica
Recruiting	`NCT06008184` - Real-time Monitoring of Cortisol - Comparison of Cortisol Levels in Four Biological Fluids
Completed	`NCT03013166` - THIN Database Study: Resource Use and Outcomes in Patients With Adrenal Insufficiency Prescribed Hydrocortisone: Immediate, or Modified Release, or Prednisolone
Enrolling by invitation	`NCT02282150` - Modified-release Compared to Conventional Hydrocortisone on Diurnal Fatigue in Secondary Hypoadrenalism	Phase 4
Completed	`NCT02934399` - Dynamic Hormone Diagnostics in Endocrine Disease
Completed	`NCT03000231` - Circadian Function and Cardio-metabolic Risk in Adrenal Insufficiency
Completed	`NCT01960530` - An Investigational Study of Hydrocortisone	Phase 1
Completed	`NCT00552487` - Isolated ACTH Deficiency in Patients With Hashimoto Thyroiditis	N/A
Completed	`NCT00575341` - Dehydroepiandrosterone Substitution in Adolescent and Young Women With Central Adrenal Insufficiency	Phase 3
Completed	`NCT00471900` - Six Months DHEA Treatment in Female Adrenal Failure	N/A
Completed	`NCT03294876` - Rheumatoid Arthritis Adrenal Recovery Study
Completed	`NCT03709381` - Effect of Adrenocorticotropic Hormone on Vascular Endothelial Growth Factor Release in Children Study	Early Phase 1
Recruiting	`NCT05639127` - The Treatment of Adrenal Crisis With Inhaled Prednisolone	Early Phase 1

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Prevalence of Adrenal Insufficiency in Kidney Transplanted Patients in Glucocorticoid Treatment

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms